Data from FDA (Food and Drug Administration, USA) - Curated by EPG Health - Last updated 04 January 2017
PRECAUTIONS General Prescribing Cephalexin for Oral Suspension USP in
Prolonged use of Cephalexin for Oral Suspension USP may result in the overgrowth of nonsusceptible organisms.
If superinfection occurs during therapy,
In hematologic studies or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side or in Coombs ' testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognized that a
Cephalexin for Oral Suspension USP should be administered with
Under such conditions,
Indicated surgical procedures should be performed in conjunction with antibiotic therapy.
Broad-spectrum antibiotics should be prescribed with
Cephalosporins may be associated with a fall in prothrombin activity.
Those at risk include patients with renal or hepatic
Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated.
Information for Patients Patients should be counseled that antibacterial drugs including Cephalexin for Oral Suspension USP should only be used to treat bacterial
They do not treat
When Cephalexin for Oral Suspension USP is prescribed to treat a bacterial
Skipping doses or not completing the full course of therapy may (1)
Sometimes after starting treatment with antibiotics,
If this occurs, patients should contact their physician as soon as
Drug Interactions Metformin - In
Although not observed in this study,
Probenecid - As with other?-lactams,
Drug/Laboratory Test Interactions As a result of administration of Cephalexin for Oral Suspension USP, a false-positive reaction for glucose in the
This has been observed with Benedict 's and Fehling 's solutions and also with Clinitest® tablets.
Tests to determine the mutagenic
In male and female
Pregnancy Teratogenic effects - Pregnancy Category B - Reproduction studies have been performed on mice and
There are, however,
Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Pediatric Use The
In these trials, pediatric patients may have received cephalexin for Oral Suspension.
Geriatric Use Of the 701 subjects in 3 published clinical studies of cephalexin, 433 (62 %) were 65 and over.
Because elderly patients are more likely to have
The most frequent side effect has been diarrhea.
It was very rarely
Dyspepsia, gastritis, and abdominal
As with some penicillins and some other cephalosporins, transient hepatitis and cholestatic jaundice have been reported rarely.
These reactions usually subsided upon discontinuation of the drug.
In some of these reactions,
Anaphylaxis has also been reported.
Other reactions have included genital and anal pruritus, genital moniliasis, vaginitis and vaginal discharge, dizziness,
Reversible interstitial nephritis has been reported rarely.
Eosinophilia, neutropenia, thrombocytopenia, hemolytic anemia, and slight elevations in AST and ALT have been reported.
In addition to the
Several cephalosporins have been implicated in triggering seizures, particularly in
If seizures associated with drug therapy should occur,
Anticonvulsant therapy can be given if clinically indicated.
Laboratory Tests - Prolonged prothrombin time,
DOSAGE AND ADMINISTRATION Cephalexin for Oral Suspension USP is administered orally.
Adults-The adult dosage ranges from 1 to 4 g daily in divided doses.
The usual adult dose is 250 mg every 6 hours.
For the following
Cystitis therapy should be continued for 7 to 14 days.
Pediatric Patients-The usual
For streptococcal pharyngitis in patients over 1 year of age and for skin and skin structure
Cephalexin for Oral Suspension Weight 125 mg/5 mL 10 kg (22 lb) 1/2 to 1 tsp q.i.d. 20 kg (44 lb) 1 to 2 tsp q.i.d. 40 kg (88 lb) 2 to 4 tsp q.i.d. Weight 250 mg/5 mL 10 kg (22 lb) 1/4 to 1/2 tsp q.i.d. 20 kg (44 lb) 1/2 to 1 tsp q.i.d. 40 kg (88 lb) 1 to 2 tsp q.i.d. or Weight 125 mg/5 mL 10 kg (22 lb) 1 to 2 tsp b.i.d. 20 kg (44 lb) 2 to 4 tsp b.i.d. 40 kg (88 lb) 4 to 8 tsp b.i.d. Weight 250 mg/5 mL 10 kg (22 lb) 1/2 to 1 tsp b.i.d. 20 kg (44 lb) 1 to 2 tsp b.i.d. 40 kg (88 lb) 2 to 4 tsp b.i.d.
In the therapy of otitis media, clinical studies have shown that a dosage of 75 to 100 mg/kg/day in
In the treatment of?-hemolytic streptococcal
|Agency product number||5SFF1W6677|
|Date Last Revised||11-09-2009|
|Type||HUMAN PRESCRIPTION DRUG|
|Marketing authorisation holder||Jazeera Pharmaceutical|